Healthcare, Pharma & Life Sciences

Ultra-Cyclist Launches 10,000-Mile 'Ride the Nation' With NewForm

Image
Ultra-Cyclist Launches 10,000-Mile 'Ride the Nation' With NewForm

Boston – September 16, 2026 -- Ultra-endurance cyclist Jack Thompson departed Boston today on a 10,000-mile, 60-day ride across all 48 contiguous U.S. states, partnering with national sobriety and mental health platform NewForm to document how American communities are building recovery and connection networks.

Thompson's 60-day route spans the continental U.S. before ending in Santa Cruz

The journey, dubbed "Ride the Nation," is scheduled to conclude around November 13 in Santa Cruz, California. Thompson will stop in communities nationwide to meet recovery groups, schools, local leaders and individuals navigating addiction, sobriety and mental health challenges.

Headlands Research Opens New Clinical Trial Site in Grand Rapids

Image
Headlands Research Opens New Clinical Trial Site in Grand Rapids

Grand Rapids – September 16, 2026 -- Headlands Research has established a new clinical trial site in Grand Rapids, Michigan, led by board-certified rheumatologist Eric Slavin, MD, FACP, FACR, expanding the network's capacity for rheumatology, autoimmune disease, and cardiometabolic trials in the Midwest.

New de novo site targets high-demand therapeutic areas

Headlands Research - Grand Rapids is currently under development and expected to open later in 2026. The site will focus on rheumatology, bone and joint conditions, and autoimmune and inflammatory diseases, while also conducting studies in general medicine, chronic kidney disease, obesity, hypertension, hyperlipidemia, and vaccines.

Kyle Burtnett, CEO of Headlands Research, said sponsor demand for rheumatology and autoimmune disease trials continues to climb, positioning the new site to address that gap in the Midwest market.

Saudi Arabia Nominates Dr Hanan Balkhy for WHO Director-General

Image
Saudi Arabia Nominates Dr Hanan Balkhy for WHO Director-General

Riyadh – September 16, 2026 -- Dr Hanan H. Balkhy, WHO Regional Director for the Eastern Mediterranean, has launched her candidacy for WHO Director-General after being nominated by the Kingdom of Saudi Arabia, pledging to build "a WHO the world can count on."

Saudi Arabia backs a 30-year public health veteran for WHO's top post

Dr Balkhy, trained in Saudi Arabia and the United States, has spent more than three decades in clinical medicine, academic research and international public health leadership. She currently oversees WHO operations across 22 Member States and more than 750 million people as Regional Director for the Eastern Mediterranean, and previously served as WHO's first Assistant Director-General for Antimicrobial Resistance and as a member of the Organization's Global Policy Group.

CytoSorbents Execs to Present at H.C. Wainwright Investor Conference

Image
CytoSorbents Execs to Present at H.C. Wainwright Investor Conference

Princeton, N.J. – – September 16, 2026 -- CytoSorbents Corporation (NASDAQ: CTSO) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14–16, 2026, as the blood-purification device maker seeks to update investors on its regulatory pipeline and path to profitability.

CEO and CFO to join fireside chat on September 14

Dr. Phillip Chan, Chief Executive Officer, and Peter Mariani, Chief Financial Officer, will join Sean Lee, Vice President of Equity Research at H.C. Wainwright, for a fireside chat at 11:30 a.m. EDT at the Lotte New York Palace Hotel. The two executives will also hold scheduled one-on-one meetings with investors during the three-day event. A webcast replay will remain archived for up to 90 days on the company's investor relations site.

Vincere Biosciences Wins $2.7M NIH Grant for Kidney Injury Drug

Cambridge, Mass. – September 16, 2026 -- Vincere Biosciences has been awarded a $2.7 million Small Business Innovation Research (SBIR) Phase II grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health, to fund IND-enabling development of its USP30 inhibitor for acute kidney injury (AKI).

NIH funding targets a disease affecting 13 million people annually

Acute kidney injury impacts more than 13 million people worldwide each year following ischemia, major surgery, or exposure to nephrotoxic drugs, yet treatment remains largely supportive. The two-year grant will fund genotoxicity and toxicology studies, 28-day GLP toxicology studies, and cardiovascular, respiratory, and CNS safety pharmacology required before Vincere can file an Investigational New Drug (IND) application.

Elanco Executives to Address Investors at Morgan Stanley Healthcare Conference

Image
Elanco Executives to Address Investors at Morgan Stanley Healthcare Conference

Indianapolis – September 16, 2026 -- Elanco Animal Health Incorporated (NYSE: ELAN) confirmed its leadership team will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026.

Top executives to field investor questions in fireside chat format

CEO Jeff Simmons, CFO Bob VanHimbergen, and Bobby Modi, executive vice president for U.S. Pet Health and Global Digital Transformation, will join a fireside chat session scheduled for 2:35 p.m. ET on September 15.

Digital transformation leadership signals strategic pivot in pet health segment

Modi's dual role overseeing both U.S. Pet Health operations and Global Digital Transformation places technology investment discussions on the agenda alongside core business performance.

BioLineRx, Hemispherian to Present GLIX1 Glioblastoma Data at EANO 2026

Image
BioLineRx, Hemispherian to Present GLIX1 Glioblastoma Data at EANO 2026

Tel Aviv and Oslo – September 16, 2026 -- BioLineRx Ltd. (NASDAQ/TASE: BLRX) and Hemispherian AS will present two abstracts on their oncology candidate GLIX1 at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) in Rome, Italy, September 24-27, with one abstract selected for oral presentation.

Labcorp Targets 5-8% Revenue Growth Through 2029 at Investor Day

Image
Labcorp Targets 5-8% Revenue Growth Through 2029 at Investor Day

Burlington, N.C. – September 16, 2026 -- Labcorp (NYSE: LH) reaffirmed its full-year 2026 guidance and unveiled a long-term outlook through 2029 projecting compound annual revenue growth of 5% to 8% and compound annual adjusted earnings per share growth of 8.5% to 11.5%, the company said at its 2026 Investor Day.

Labcorp projects adjusted operating margin expansion of 75 to 150 basis points by 2029

The diagnostics and drug development laboratory company also targets compound annual free cash flow growth in line with adjusted earnings growth through the same period. Guidance assumes foreign exchange rates effective as of September 16, 2026, and reflects anticipated capital allocation including acquisitions, share repurchases and dividends.

Munich Pharmacy Roadshow Draws 3,000 Ahead of German Apothekertag

Image
Munich Pharmacy Roadshow Draws 3,000 Ahead of German Apothekertag

Munich – September 16, 2026 -- Up to 3,000 registered pharmacists, pharmacy technicians (PTA) and pharmacy clerks (PKA) are set to attend the APOTHEKENTOUR in Munich on September 12-13, the event's second stop after Berlin drew more than 2,500 attendees and a 15% year-on-year increase in visitors.

Munich stop packs 170 talks and pharma-partner cases into one weekend

The Munich edition, powered by APOTHEKE ADHOC and PTA IN LOVE, will feature more than 170 lectures, several live talks and new product showcases connecting attendees directly with pharmaceutical industry partners. The event is scheduled deliberately the weekend before the Deutscher Apothekertag, where Health Minister Carsten Linnemann (CDU) is expected to address the sector's political future.

Donate Life America Names Madison Walter-Garcia as Next President & CEO

Image
Donate Life America Names Madison Walter-Garcia as Next President & CEO

Richmond, Va. – September 16, 2026 -- Donate Life America (DLA) has named Madison Walter-Garcia, MPH, CHES, as its next President & CEO, effective September 21, succeeding David Fleming after more than 30 years of leadership.

Walter-Garcia Brings Nearly a Decade of CDC Partnership Experience to DLA

Walter-Garcia spent nearly ten years at the Centers for Disease Control and Prevention (CDC), most recently as Associate Director for Partnerships in the Division of Foodborne, Waterborne, and Environmental Diseases. She built partnership programs from the ground up, cultivated relationships with more than 1,000 stakeholders, and led a gift portfolio through the CDC Foundation exceeding $30 million.